First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2012-05-31 05:34:33Open Document File Size: 4,67 MBShare Result on FacebookCityOslo / Marocco / Kalundborg / /CompanyTakeda Pharmaceutical / Herkules Private Equity Fund / Par Pharmaceutical Inc. / Oslo Stock Exchange / COMMERCIAL PARTNERS / Teva Pharmaceuticals USA Inc. / Pronova BioPharma Group / Sandoz Inc. / Apotex Inc. / Pronova BioPharma ASA / GlaxoSmithKline / Endo Pharmaceuticals / Apotex Corp. / Pfizer Italia / Abbott Laboratories / Par Pharmaceutical Companies Inc. / /ContinentAsia / Europe / /CountryTaiwan / Germany / Venezuela / Netherlands / Italy / Macedonia / South Africa / Egypt / Norway / Belgium / France / Malaysia / Japan / Russia / United States / Brazil / Vietnam / Canada / Australia / Portugal / Korea / United Kingdom / China / Argentina / Spain / Greece / India / Ireland / Denmark / /CurrencyUSD / /EventLegal Issues / FDA Phase / Business Partnership / /FacilityGroup’s plant / NEW LIPID DRUG PIPELINE / United States District Court / /HolidayCommonwealth Day / /IndustryTermpharmaceutical drug / pharmaceutical drug candidates / supply chain / pharmaceutical product / proposed generic drug products / pharmaceutical / consumer healthcare space / prevention of cardiovascular disease / commercialised pharmaceutical product / treatment of cardiovascular / metabolic and inflammatory diseases / blockbuster product / efficacious products / pharmaceutical market / consumer healthcare / health bringing products / pharmaceutical products / generic products / life-cycle management / manufacturing advantage / manufacturing yield increase / /MedicalConditionmetabolic and inflammatory diseases / cardiovascular diseases / cardiovascular disease / heart attack / post-myocardial infarction / /MusicAlbumCentral / South America / /OrganizationGerman Federal Patent Court / Commonwealth of Independent States / United States District Court for the District of Delaware / DHA / US Food and Drug Administration / American Heart Association / Environmental Protection Agency / /PersonPierre Fabre / Pierre Fabre Médicament / /Positionhonesty and innovation PIONEER AND LEADER / player / head / Major / important player in the non-statin cardiovascular segment / /ProductOmacor / Lovaza / HEART PATIENTS CAPSULES / prescription drug / USA / Lovaza™ / Q3 / /ProvinceOrStateDelaware / /RegionMiddle East / North Africa / Central America / East Asia / South America / SouthEast Asia / South Korea / Eastern Europe / Central Africa / /SocialTag |